Moderate ResearchLongevityImmune

Chonluten

EDG

EDG Tripeptide | Bronchial/Lung Bioregulator

Half-life

Minutes (short peptide); effects persist via epigenetic changes

Chain length

3 amino acids

Reference frequency

Once daily for 10-20 consecutive days

Research overview

DoseGear research brief

Chonluten is a Khavinson bioregulator tripeptide (EDG) derived from respiratory lung tissue. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it targets the bronchopulmonary system with secondary activity in the GI tract. Research shows it regulates genes related to inflammation, antioxidant activity, and proliferation responses. Chonluten inhibits TNF production in monocytes and has been studied as a potential geroprotective agent that may support lung function in conditions like COPD.

Mechanism of action

Chonluten works through epigenetic regulation, penetrating cell and nuclear membranes to bind promoter or suppressor regions of DNA and modulate transcriptional control. It regulates genes including c-Fos, HSP70 (heat-shock protein), SOD (superoxide dismutase), COX-2, and TNF-alpha related to oxidative stress and proliferative regulation. The peptide inhibits TNF production in monocytes exposed to pro-inflammatory LPS, promoting attenuation of inflammatory action through TNF tolerance mechanisms.

Compound background

Development & research timeline

Study windows describe what researchers measured, not when an individual should expect a result.

Origin & development

EDG tripeptide attributed to St. Petersburg and Khavinson respiratory-tissue research.

What it is researched for

Experimental pulmonary inflammation and tissue regulation through proposed inflammatory and antioxidant gene-expression effects.

Research observation window

Not reported in the reviewed compound-specific evidence.

Reference data

Lyophilized vial injectable protocols

Not personalized dosing instructions

Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.

Research context	Amount	Frequency	Route
Chart reference	250 mcg	Daily · See source guide	Injectable · 20 mg lyophilized vial + 3 mL BAC Water

Reference cycle

10-20 days per cycle

Reference storage

Capsules: room temperature; Injectable lyophilized: 2-8°C; Reconstituted: 2-8°C refrigerated

Safety context

Reported side effects

Generally well-tolerated
Minimal side effects reported

Contraindications & cautions

Active respiratory emergencies (seek medical care)
Known hypersensitivity
Pregnancy or breastfeeding

Scientific references

01
Peptides Regulating Proliferative Activity and Inflammatory Pathways in THP-1 Cells
Scientific citationPeptides Regulating Proliferative Activity and Inflammatory Pathways in THP-1 Cells. PMC/NCBI (2022).
02
Chonluten and Gene Expression Regulation
Scientific citationChonluten and Gene Expression Regulation. Advances in Gerontology (2018).
03
Bronchial Bioregulator Peptides
Scientific citationBronchial Bioregulator Peptides. Bulletin of Experimental Biology and Medicine (2016).
04
Khavinson Peptide Bioregulators
Scientific citationKhavinson Peptide Bioregulators. Advances in Gerontology (2020).

This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.

Related research profiles

Longevity